Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Share-based Compensation (Tables)

Share-based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Share-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying condensed consolidated statements of comprehensive loss for the three and six month periods indicated below (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
General and administrative	$	288	$	159	$	481	$	201
Research and development		175		157		476		176
Total share-based compensation	$	463	$	316	$	957	$	377

Weighted Average Assumptions Used in Black-Scholes Option-pricing Model

The weighted‑average assumptions used in the Black‑Scholes option‑pricing model are as follows during the three and six months ended June 30, 2021 and 2020:

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Expected stock price volatility		99.2	%		95.5	%		97.2	%		95.5	%
Expected life of options (years)		5.8			10.0			5.8			10.0
Expected dividend yield		0	%		0	%		0	%		0	%
Risk free interest rate		0.9	%		0.7	%		0.9	%		0.7	%